Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Anxiolytika im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Außerdem werden Substanzen besprochen, deren primäre Indikation außerhalb der Angststörungen liegt, die aber auch bei diesen wirksam sind.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Baandrup L, Fasmer OB, Glenthø BY et al (2016) Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trial. BMC Psychiatry 16(1): 348
Bonnet U, Scherbaum N (2017) How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 27: 1185–1215
Buoli M, Grassi S, Serati M et al (2017) Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother 18(13): 1373–1379
Bürgy M (2017) Die wahnhafte Depression. Nervenarzt 88: 529–537
Chen TY, Winkelman JW, Mao WC et al (2018) The use of benzodiazepine receptor agonists and the risk of hospitalization for pneumonia: a nationwide population-based nested case-control study. Chest 153(1): 161–171
Fond G, Berna F, Boyer L et al (2018) Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci 268(1): 17–26
Gahr M, Hiemke C, Connemann BJ (2017) Update Opipramol. Fortschr Neurol Psychiatr 85: 139–145
Gottschalk MG, Domschke K (2018) Oxytocin and anxiety disorders. Curr Top Behav Neurosci 35: 467–498
Hata T, Kanazawa T, Hamada T et al (2018) What can predict and prevent the long-term use of benzodiazepines? J Psychiatr Res 97: 94–100
Kasper S, Volz HP, Dienel A, Schläfke S (2016) Efficacy of silexan in mixed anxiety-depression – a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 26: 331–340
Klass A, Glaubitz B, Tegenthoff M et al (2017) D-Cycloserine facilitates extinction learning and enhances extinction-related brain activation. Neurobiol Learn Memory 144: 235–247
Lüddens H (2012) Anxiolytika und Hypnotika. In: Gründer G, Benkert O (Hrsg) Handbuch der Psychopharmakotherapie, 2. Aufl. Springer, Berlin Heidelberg New York, S 695–712
Mataix-Cols D, Fernández de la Cruz L, Monzani B et al (2017) D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiatry 74(5): 501–510
Meier SM, Mattheisen M, Mors O et al (2016) Increased mortality among people with anxiety disorders: total population study. Br J Psychiatry 209: 216–221
Meyer B, Yuen KS, Ertl M et al (2015) Neural mechanisms of placebo response. J Neursci 35(19): 7365–7373
Pollack MH, van Ameringen M, Simon NM et al (2014) A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry 171: 44–53
Schjerning O, Damkier P, Lykkegaard SE et al (2017) Pregabalin for anxiety in patients with schizophrenia – a randomized, double-blind placebo-controlled study. Schizophr Res pii: S0920-9964(17)30575-3
Soyka M (2017) Treatment of benzodiazepine dependence. N Eng J Med 376: 1147–1157
Stubbs B, Vancampfort D, Rosenbaum S et al (2017) An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: a meta analysis. Psychiatry Res Vol 249: 102–108
Weber SR, Wehr AM, Duchemin AM (2016) Prevalence of antipsychotic prescriptions among patients with anxiety disorders treated in inpatient and outpatient psychiatric settings. J Affect Disord 191: 292–299
Wolter DK (2017) Benzodiazepine absetzen im Alter. Wann und, wenn ja, wie? Z Gerontol Geriatr 50: 115–122
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Anghelescu, IG., Benkert, O. (2019). Anxiolytika. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57334-1_4
Download citation
DOI: https://doi.org/10.1007/978-3-662-57334-1_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57333-4
Online ISBN: 978-3-662-57334-1
eBook Packages: Medicine (German Language)